Helminthiasis

AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024

Retrieved on: 
星期二, 四月 16, 2024
Fetus, AMGN, American Thoracic Society, Congress, Arthralgia, ATS, Chronic obstructive pulmonary disease, Emphysema, Pregnancy, Infection, Tezepelumab, PDT, Allergic conjunctivitis, Amgen, Research and development, Back pain, Conference, Placentalia, Vaccine, Miscarriage, Development, Ageing, Helminthiasis, Incidence, Patient, Anaphylaxis, Hypersensitivity, Rash, Pharyngitis, Birth, Asthma, Bronchitis, AstraZeneca, Excipient, Pharmaceutical industry

THOUSAND OAKS, Calif., April 16, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American Thoracic Society (ATS) 2024 International Conference on Monday, May 20, from 9:15-11:15 a.m. PDT. 

Key Points: 
  • Overall, tezepelumab numerically reduced the annualized rate of moderate or severe COPD exacerbations versus placebo by 17% (90% CI: −6, 36; p=0.1042).
  • Of note, more reductions were observed in a prespecified subgroup of patients with BEC ≥150 cells/μL (37% [95% CI: 7, 57]).
  • The trend in reduction was greater in a small number of subjects with BEC ≥300 cells/µL.
  • We look forward to presenting the full data set at the congress and based on these findings, we are actively planning for the Phase 3 development of tezepelumab in COPD.

Can the bugs in our guts help us manage inflammation?

Retrieved on: 
星期二, 一月 30, 2024
Immunity, Eshleman, Inflammation, Extrapyramidal system, Cell, Research, Immune system, Allergy, Bacteria, Helminthiasis, VMD, News, Patient, Virus, Food, Food allergy, Nutrient, Diet, Organoid, Mouse, B cell, Dietary fiber, Learning, Fungus, Parasitism, HDAC3, Dicarboxylic acid, Doctor of Philosophy, Health, Asthma, Infection, Vaccine

CINCINNATI, Jan. 30, 2024 /PRNewswire/ -- Imagine a day when people can enjoy snacking on foods designed to "re-calibrate" their microbiomes—that vast population of friendly bacteria living in our intestines—in order to promote a healthy immune system and decrease infections or chronic inflammation.

Key Points: 
  • Scientists have studied the intestine for many years, but even now they are learning surprising details about how it works.
  • "This study shows that the microbiota—and products made by the microbiota—can dynamically control immune responses in the gut," Alenghat says.
  • The research examines a reaction called type 2 immunity that occurs with chronic inflammatory conditions such as allergy and asthma.
  • Until now, it was not clear if nor how the gut microbiome impacts tuft cells.

Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)

Retrieved on: 
星期四, 一月 25, 2024
Ageing, Regeneron Pharmaceuticals, Patient, Histology, Failure, Diagnosis, Medicine, Heartburn, Risk, Lower respiratory tract infection, Food, Arthralgia, Chronic pain, Safety, Disease, Esophagus, Inflammation, Helminthiasis, Priority review, FDA, Eosinophilic esophagitis, Prevalence, Vomiting, International development, Growth, Pharmaceutical industry

TARRYTOWN, N.Y. and PARIS, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for the treatment of pediatric patients aged 1 to 11 years, weighing at least 15 kg, with eosinophilic esophagitis (EoE). Dupixent is now the first and only medicine approved in the U.S. specifically indicated to treat these patients. This approval expands the initial FDA approval for EoE in May 2022 for patients aged 12 years and older, weighing at least 40 kg. The FDA evaluated Dupixent for this expanded indication under Priority Review, which is reserved for medicines that represent potentially significant improvements in efficacy or safety in treating serious conditions.

Key Points: 
  • Dupixent is now the first and only medicine approved in the U.S. specifically indicated to treat these patients.
  • This approval expands the initial FDA approval for EoE in May 2022 for patients aged 12 years and older, weighing at least 40 kg.
  • Approximately 21,000 children under the age of 12 in the U.S. are currently being treated for EoE with unapproved therapies.
  • “With this approval, Dupixent becomes the first and only treatment option for EoE patients aged 1 and older, weighing at least 15 kg.

Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE)

Retrieved on: 
星期四, 一月 25, 2024
Ageing, Patient, Histology, Failure, Diagnosis, Medicine, Heartburn, Risk, Lower respiratory tract infection, Food, Arthralgia, Chronic pain, Safety, Disease, Esophagus, Helminthiasis, FDA, Priority review, Inflammation, Eosinophilic esophagitis, Vomiting, Prevalence, Growth, Pharmaceutical industry

The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for the treatment of pediatric patients aged 1 to 11 years, weighing at least 15 kg, with eosinophilic esophagitis (EoE).

Key Points: 
  • The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for the treatment of pediatric patients aged 1 to 11 years, weighing at least 15 kg, with eosinophilic esophagitis (EoE).
  • Dupixent is now the first and only medicine approved in the U.S. specifically indicated to treat these patients.
  • This approval expands the initial FDA approval for EoE in May 2022 for patients aged 12 years and older, weighing at least 40 kg.
  • With this approval, Dupixent becomes the first and only treatment option for EoE patients aged 1 year and older, weighing at least 15 kg.

American Lung Association Funds $13.6 Million in Research for a Future Free of Lung Disease

Retrieved on: 
星期四, 十月 12, 2023
Havasupai Tribe v. the Arizona Board of Regents, Manning Innovation Awards, T helper cell, Immunotherapy, COVID-19, Omicron, Lung cancer, Tropism, Icahn School of Medicine at Mount Sinai, Asthma, University of Arizona, Natural killer T cell, Research, COPD, Boston University, Immunoglobulin E, University, Disease, Lung, Patient, Award, American Lung Association, CHI3L1, Canadian Lung Association, Immunology, Helminthiasis, Trustee, Research institute, Infection, SARS-CoV-2, RSV, TFH, Blood, Mount Sinai, Pharmaceutical industry, Vaccine, School

CHICAGO, Oct. 12, 2023 /PRNewswire/ -- Today, the American Lung Association Research Institute announced it awarded $13.6 million in research grants to fund 129 innovative projects to advance today's science to end the burden of lung disease tomorrow. Lung research is critical because one in 10 people in the U.S. are living with a lung disease and each year, millions of people are impacted by respiratory viruses like COVID-19 and influenza.

Key Points: 
  • Organization funds 129 promising research grants on lung cancer, asthma, COVID-19 and more
    CHICAGO, Oct. 12, 2023 /PRNewswire/ -- Today, the American Lung Association Research Institute announced it awarded $13.6 million in research grants to fund 129 innovative projects to advance today's science to end the burden of lung disease tomorrow.
  • Through the Awards and Grants Program, the Lung Association supports trailblazing research, novel ideas and innovative approaches.
  • The Lung Association's Awards and Grants Program promotes innovative research, collaboration, translation of discoveries and scientific exchange to transform today's science into tomorrow's solutions," said Harold Wimmer, President and CEO of the American Lung Association.
  • For more information about the new grant awardees and the entire American Lung Association research team, visit Lung.org/research-team .

Ringworm fungal infections are common in the US and are becoming increasingly resistant to treatment – 6 questions answered

Retrieved on: 
星期四, 六月 29, 2023
Infection, Hair, Human, Conversation, Epidermophyton, Griseofulvin, Skin, Fungal infection, Prevalence, Dermatophytosis, Hyperhidrosis, Atmosphere, Hair loss, Cracked, Finger, Health, Nail, Clothing, The, Livestock, Global health, Hypha, Lupus, Cell, Fungus, New York State Department of Health, Rash, CDC, Athlete, Plant, Death, Antimalarial medication, Helminthiasis, Terbinafine, Animal, Soil, Population, Patient, Wrestling, Immune system, Autoimmune disease, Pet, Yeast, World Health Organization, Growth, Tolnaftate, Bacteria, Center, Research, World, Microsporum, Itraconazole, Pharmaceutical industry, Vaccine, Sulfur, Truffle, Self storage, Cosmetics, Fungiculture, Sports equipment, Trichophyton, Clotrimazole

The World Health Organization considers antimicrobial resistance to be one of the most serious threats for global health.

Key Points: 
  • The World Health Organization considers antimicrobial resistance to be one of the most serious threats for global health.
  • Similar to the way bacteria have developed resistance to antibiotics, fungal infections throughout the world are becoming more drug-resistant and more deadly.

1. What is ringworm and how common is it?

    • However, a ringworm infection is a common infection of the skin caused by a fungus.
    • Experts state that about 20%-25% of the population will experience a ringworm infection at any given time.
    • Research shows that there are up to 40 types of fungus that can cause these ringworm infections, with the most common types being from the genuses Trichophyton, Microsporum or Epidermophyton.
    • Medical terms for ringworm are “tinea” and “dermatophytosis.” Tinea and dermatophytosis are synonyms for a contagious fungal infection of the skin.

2. How can you recognize ringworm?


    The hair, skin and nails of either fingers or toes are the likely landing spots for a ringworm infection. Signs and symptoms of an infection usually depend on which part of the body is affected, but generally may include hair loss and red, scaly, cracked skin. However, the most well-known sign that gives this infection its ironic and misplaced name – ringworm – is the hallmark ring-shaped rash.

3. How does ringworm spread?

    • Fungi can grow in two forms: yeasts, which are single round cells, and molds, which are made up of many cells forming long, thin, hairlike threads called hyphae.
    • Some of them can exhibit both forms of growth and thrive in decaying organic material like soil or a plant.
    • Ringworm occurs more frequently in tropical areas and during hot, humid summers.

4. How can you reduce the likelihood of getting it?

    • Some of the best ways to reduce or prevent a ringworm or other fungal infection include: – Wash hands with soap and warm water.
    • – Wear shoes and socks that are made of lightweight, breathable materials to reduce moisture.
    • – Avoid walking barefoot in wet or humid areas like locker rooms or public showers.

5. What treatments are there?

    • There are several treatment options, including antifungal medications prescribed by a physician or dermatologist or over-the-counter products sold as a cream or ointment.
    • Finally, in some cases a person may need to use antifungal shampoo and soap to clean themselves and sterilize bedding and clothing.

6. Why is antifungal resistance a growing problem?

    • Antimicrobial resistance, including antifungal resistance, is an ongoing global emergency.
    • Experts estimate that drug-resistant infections caused roughly 1.3 million deaths around the world in 2019.
    • Experts believe that inappropriate use of topical antifungal and corticosteroid medications is likely driving its spread.

TEZSPIRE® APPROVED FOR SELF-ADMINISTRATION IN THE U.S. WITH A NEW PRE-FILLED PEN

Retrieved on: 
星期四, 二月 2, 2023
Caregiver, Vaccine, Helminthiasis, Tezepelumab, Ageing, Allergy, Rash, Asthma and Allergy Foundation of America, Medicine, Placentalia, Pharyngitis, Phenotype, Maintenance, Excipient, Patient, Incidence, Asthma, Back pain, Pregnancy, Fetus, Food, Severe cutaneous adverse reactions, Hypersensitivity, Allergic conjunctivitis, Amgen, Birth, FDA, Infection, AMGN, Miscarriage, AstraZeneca, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Anaphylaxis, European, Arthralgia, Acute exacerbation of chronic obstructive pulmonary disease, Pharmaceutical industry, Dietary supplement, EU

THOUSAND OAKS, Calif., Feb. 2, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced the U.S. Food and Drug Administration (FDA) has approved TEZSPIRE® (tezepelumab-ekko) for self-administration in a pre-filled, single-use pen for patients aged 12 years and older with severe asthma.1 First approved by the FDA in December 2021, TEZSPIRE is the only biologic approved for severe asthma with no phenotype (e.g., eosinophilic or allergic) or biomarker limitation within its approved label.2-9

Key Points: 
  • "We believe self-administration alternatives can play an important role in patients' lives and address unmet needs for those living with severe asthma."
  • TEZSPIRE is currently approved for the treatment of severe asthma in the U.S., EU, Japan and other countries.
  • TEZSPIRE is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.
  • Hypersensitivity reactions were observed in the clinical trials (e.g., rash and allergic conjunctivitis) following the administration of TEZSPIRE.

Outlook on the Neglected Tropical Diseases Diagnosis Global Market to 2030 - Featuring Abbott, Thermo Fisher Scientific and Zeptometrix Among Others - ResearchAndMarkets.com

Retrieved on: 
星期四, 五月 26, 2022
Health, Biotechnology, Centralisation, Population, Infection, NTD, Neglected tropical diseases, Gold, IVD, Novartis, Helminthiasis, Global Television Network, Awareness, WHO, POCT, Technology, Global Network for Neglected Tropical Diseases, STHS, PCR, Adoption, Growth, Prevalence, Diagnosis, Lists of countries and territories, Medical device

This growth in concern is evident in the launch of a substantial number of programs aiming to combat NTDs.

Key Points: 
  • This growth in concern is evident in the launch of a substantial number of programs aiming to combat NTDs.
  • For instance, the Global Network for Neglected Tropical Diseases aims to raise awareness and funding, both of which are essential to control and eliminate the most common NTDs.
  • In addition, various companies are undertaking efforts to develop less complicated and inexpensive diagnostic assays for tropical diseases.
  • Chapter 3 Neglected Tropical Diseases Diagnosis Market Variables, Trends & Scope

Press Release: Dupixent® (dupilumab) approved by European Commission for children aged 6 to 11 years with severe asthma with type 2 inflammation

Retrieved on: 
星期四, 四月 7, 2022
EOS, Wheeze, Conditional sentence, Prurigo nodularis, Clinical trial, Sex, Patient, Interleukin, Skin, European Commission, Ageing, ICS, EC, Regeneron Pharmaceuticals, Eosinophilic esophagitis, The Rheumatoid Arthritis Quality of Life Questionnaire, Safety, Hope, Union, Polyp (medicine), Nitric acid, Asthma, Sinusitis, Allergic rhinitis, Maintenance, Helminthiasis, Cough, FEV1, Atopic dermatitis, Eosinophilia, Pharmaceutical industry, EU, Dupilumab

The European Commission (EC) has expanded the marketing authorization for Dupixent (dupilumab) in the European Union.

Key Points: 
  • The European Commission (EC) has expanded the marketing authorization for Dupixent (dupilumab) in the European Union.
  • Up to 85% of children with asthma may have type 2 inflammation and are more likely to have higher disease burden.
  • Children with severe asthma also may require the use of multiple courses of systemic corticosteroids that carry significant risks.
  • In clinical trials, Dupixent significantly reduced asthma attacks, helped children breathe better and improved their health-related quality of life.

TEZSPIRE™ (TEZEPELUMAB-EKKO) NOW AVAILABLE IN THE UNITED STATES FOR THE TREATMENT OF SEVERE ASTHMA

Retrieved on: 
星期四, 一月 13, 2022
Biomarker, Medicine, Ageing, SOC, Patient, Vaccine, Incidence, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, Population, Excipient, Adult, NASDAQ, Program, Rash, TSLP, Helminthiasis, Back pain, Disease, Placentalia, Amgen, Birth, Asthma, Acute exacerbation of chronic obstructive pulmonary disease, Standard of care, Pharyngitis, Pregnancy, AstraZeneca, ICS, Allergic conjunctivitis, Fetus, Caregiver, Miscarriage, Nitric acid, Arthralgia, Food, AMGN, Infection, Hypersensitivity, FDA, Maintenance, Cell, Physician, Pharmaceutical industry, Dietary supplement, Health insurance

The Tezspire Together Program offers provider and patient product resources and support, including information related to coverage, reimbursement and distribution.

Key Points: 
  • The Tezspire Together Program offers provider and patient product resources and support, including information related to coverage, reimbursement and distribution.
  • TEZSPIRE is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.
  • TEZSPIRE should not be used to treat acute asthma symptoms, acute exacerbations, acute bronchospasm, or status asthmaticus.
  • If patients become infected while receiving TEZSPIRE and do not respond to anti-helminth treatment, discontinue TEZSPIRE until infection resolves.